International Whistleblower & Foreign Currupt Practices Act Information

International Whistleblower Rewards and Exposing International Illegal Bribe Schemes

by The Law Offices of Jason S. Coomer, PLLC

Map Of The World

India Whistleblower Rewards: Large Financial Rewards Are Being Offered to International Professionals and India Whistleblowers Who Anonymously and Properly Expose Signficant Bribery Schemes and other Foreign Corrupt Practices Act Violations by India Whistleblower Reward Lawyer, India Contract Bribe Bounty Action Lawyer, and India International Foreign Corrupt Practices Act Whistleblower Reward Lawyer Jason S. Coomer

India government official bribes and India government corruption has prevented India's economy from keeping pace with China's economic growth.  These corrupt practices include telecommunications and construction contract bribes as well as supply chain manufacturing fraud. India whistleblowers and  international whistleblowers with knowledge of corrupt practices and supply chain fraud are being offered large economic rewards for being the first to properly blow the whistle on foreign corrupt practices under the Foreign Corrupt Practices Act and fraud under other whistleblower reward laws.

For information on reporting India Foreign Corrupt Practices Act violations, India adulterated pharmaceuticals, India contract bribes, or illegal bribes and fraud along the supply chain, please feel free to send an e-mail message to India Contract Bribe Whistleblower Reward Lawyer, India Adulterated Drug Whistleblower Lawyer, and India Foreign Corrupt Practices Act Lawyer Jason Coomer or use our submission form.

India is an Emerging Industrialized Nation with a Rapidly Growing GDP and a Developing Infrastructure

India, officially Republic of India, (Bhārat Gaṇarājya) has a population of over 1.2 trillion people and is the second largest country in the world and the most populous democracy in the world.  The Indian economy is the world's tenth-largest by nominal GDP and third-largest by purchasing power parity (PPP). Following market-based economic reforms in 1991, India became one of the fastest-growing major economies and it is considered an emerging industrialized nation. 

India’s growth over the last decade has resulted in increased demand for products and services from countries like the United States. According to the International Monetary Fund’s (IMF) World Economic Outlook, from 2001-2011 India’s Gross Domestic Product (GDP) has averaged 7.8 percent growth, more than double the world average of 3.8 percent. During this time, United States’ exports to India have grown from less than $4 billion in 2001 to over $21 billion in 2011, a 475% increase in just a decade.

The IMF projects India’s GDP growth will continue to outpace the world average over the next five years. Going forward, India is expected to spend over $1 trillion on infrastructure development over the next five years, and a growing consuming class could lead to increased demand for a range of consumer goods and services. This growth represents tremendous opportunities for U.S. businesses, which is why Secretary Bryson is in India this week. For more information, follow the Secretary’s trip on the Commerce Blog.

Indian Economic Growth Has Been Undermined by Corruption Resulting in an Estimated $462 Billion Loss

According to economic and business experts, India’s economic expansion has been being undermined by corruption. But for Indian government corruption, India's economic growth should have been close to China’s pace of more than 9 percent.  According to the KPMG LLP March survey of chief executive officers in India, this corruption is a significant lag on the Indian economy.

Further, according to The Drivers and Dynamics of Illicit Financial Flows from India: 1948-2008, a report released by Washington-based, Global Financial Integrity, post Independence, India lost a staggering $462 billion in illicit financial flows due to tax evasion, crime and corruption. The report also stated that some 68 per cent of India's aggregate illicit capital loss occurred after India's economic reforms in 1991, indicating that deregulation and trade liberalisation actually contributed to/accelerated the transfer of illicit money abroad.

Corruption seriously affects India's business and political environment, posing a challenge to the country's economic growth. An increasing number of corruption scandals since the late 2000s have damaged the government's credibility, caused major loss in tax revenues, led to social unrest and widened income inequality. Corruption has become more endemic since the late 2000s along with the country's strong economic growth and a surge in investment.

India has been hit by a string of huge corruption scandals including a multi-billion dollar telecom licenses scam in 2008, alleged financial malpractices associated with the Commonwealth Games in 2010 and the illegal mining scandal in Karnataka state during 2006-2010;

India ranked 87th place out of 178 countries in Transparency International's Corruption Perceptions Index (CPI) in 2010, down from 84th place in 2009. The index refers to perceptions of the degree of corruption as seen by business people and country analysts. With this ranking, corruption in India is seen to be worse than in China and Brazil, but still less severe than in Russia and Indonesia.

India Takes Action to Reduce Corruption But the Fight Against Institutionalized Corruption is Difficult

The Indian government has taken some action against corruption by working to pass anti-corruption laws that are aimed at reducing corruption and protecting the Indian people for new multi-billion dollar contract bribes and corruption scandals.  On August 4th, 2011, the government drafted a new bill to set up an anti-corruption watchdog. The bill was criticized because it exempted the prime minister and senior judges from prosecution while they are in office.  However, on August 28th, the government accepted the first draft of a stronger anti-corruption bill proposed by Anna Hazare. There are further stages in passing the bill however, and as of March 31, 2012, the Lokpal bill is still in the process of being passed.

Development of India's Infrastructure Creates Potential for India Construction Bribes, India Public Works Bribes, and other Public Procurement Bribes

The Government of India plans to spend $1 trillion between 2012 and 2017 on infrastructure development.  This government spending constitutes a significant portion of the real estate and construction industry that may be subject to illegal construction bribes and procurement bribes from multinational corporations.  Despite the importance that infrastructure development has in a nation's progress, the level of bribery and corruption in the sector is relatively high and could result in substandard buildings as well as significant government waste.

It is widely accepted that foreign bribery has significant adverse effects on public well-being around the world. It distorts the fair awarding of contracts, reduces the quality of basic public services, limits opportunities to develop a competitive private sector and undermines trust in public institutions.  Engaging in bribery also creates instability for companies themselves and presents ever-growing reputational and financial risks. This is particularly relevant in light of recent anti-bribery reforms in a number of key countries around the world, such as in China, Russia, Brazil, the United Kingdom, and hopefully India in the near future.

India Supply Chain Fraud Can Create Adulterated Drugs, Defective Medical Supplies, Defective Medical Devices, and other Defective Products that can Result in False Claims Act Qui Tam Whistleblower Recovery Lawsuits

Through globalization of international trade, there have been shifts in many international manufacturing supply chains. These shifts include raw material supplies for numerous products including pharmaceuticals, medical supplies, electronics, food, and medical equipment that have traditionally come from the United States and Europe are now coming from India and China. This manufacturing shift has created an environment where adulterated ingredients to pharmaceuticals, medical supplies, medical devices, and other products may be used in the manufacturing of these important products and can create dangerous and defective drugs, medical supplies, medical devices, and other products. International Whistleblowers along the pharmaceutical supply chain are needed to blow the whistle on adulterated pharmaceutical ingredients and other defective false certified products that are being put into medicine, drugs, medical supplies, medical devices, and other.

Where these defective pharmaceutical ingredients and other products are used in products purchased by a governmental entity in the United States, there are potential qui tam whistleblower reward actions that may apply and allow international whistleblowers to collect a large reward for properly reporting and exposing the supply chain fraud.


Department of Justice
Office of Public Affairs

FOR IMMEDIATE RELEASE
Monday, March 26, 2012

Third Medical Device Company Resolves Foreign Corrupt Practices Act Investigation

Indiana-Based Biomet Inc. Agrees to Pay $17.2 Million for Bribes in Latin America and China

WASHINGTON – Biomet Inc. has entered into a deferred prosecution agreement with the Department of Justice to resolve improper payments by the company and its subsidiaries in violation of the Foreign Corrupt Practices Act (FCPA), announced the Justice Department’s Criminal Division.  

 

The matter is part of an investigation into bribery by medical device companies of health care providers and administrators employed by government institutions.   Previously, Johnson & Johnson and Smith & Nephew Inc. have agreed to pay criminal penalties and entered into deferred prosecution agreements related to the ongoing investigation.

 

Biomet, headquartered in Warsaw, Ind., manufactures and sells medical devices worldwide and is listed on the NASDAQ.   According to the criminal information filed today in U.S. District Court in the District of Columbia in connection with the agreement, Biomet, its subsidiaries, employees and agents made various improper payments from approximately 2000 to 2008 to publicly-employed health care providers in Argentina, Brazil and China to secure lucrative business with hospitals.   During this time, more than $1.5 million in direct and indirect corrupt payments were made.   In addition, at the end of each fiscal year, Biomet, its executives, employees and agents falsely recorded the payments on its books and records as “commissions,” “royalties,” “consulting fees” and “scientific incentives” to conceal the true nature of the payments.

 

As part of the agreement, Biomet will pay a $17.28 million criminal penalty and is required to implement rigorous internal controls, cooperate fully with the department and retain a compliance monitor for 18 months.  The agreement recognizes Biomet’s cooperation with the department’s investigation; thorough and wide-reaching self-investigation of the underlying conduct; and the remedial efforts and compliance improvements undertaken by the company.   In addition, Biomet received a reduction in its penalty as a result of its cooperation in the ongoing investigation of other companies and individuals.

 

In a related matter, Biomet reached a settlement today with the U.S. Securities and Exchange Commission (SEC), under which Biomet agreed to pay $5.4 million in disgorgement of profits, including pre-judgment interest.

 

This case is being prosecuted by Trial Attorney Kathleen M Hamann of the Criminal Division’s Fraud Section and was investigated by the FBI’s Washington Field Office’s dedicated FCPA squad.  

 

The Justice Department acknowledges and expresses its appreciation for the significant coordination with and assistance by the staff of the SEC’s Division of Enforcement.

India and United States International Trade Continues to Increase

India’s growth over the last decade has resulted in increased demand for products and services from countries like the United States. From 2001-2011 United States’ exports to India have grown from less than $4 billion in 2001 to over $21 billion in 2011, a 475% increase in just a decade.  There are now numerous products imported and exported between India and the United States including: textiles; precious stones & metals; mineral fuel and oils; pharmaceutical products; organic chemicals; machinery; electrical machinery; iron & steel products; optical instruments & equipment; fertilizers; and plastic.

Textiles exports accounted for 19.3% of India’s exports to the US in 2010. Textile exports grew from $ 4.86 billion in 2009 to reach $ 5.69 billion in 2010, an increase of 17.1%.  Exports of pharmaceutical products grew from $ 1.66 billion in 2009 to $ 2.39 billion in 2010, an increase of 43.8%.  Exports of mineral fuel, oil grew from $0.43 billion in 2009 to $ 2.32 billion in 2010, an increase of 437%. Exports of organic chemicals grew by 5.6% from $ 1.31 billion in 2009 to $ 1.72 billion in 2010.

The United States exports to India included precious stones and metals which accounted for 21.9% of exports from US to India grew by 80% to reach $ 4.21 billion in 2010 from $ 2.34 billion in 2009.  United States exports of machinery grew by 14.9% from $ 2.32 billion in 2009 to $ 2.67 billion in 2010. U.S. Exports of electrical machinery grew by 5.23% from $ 1.3 billion in 2009 to $1.37 billion in 2010.

Though U.S. exports of aircraft, aviation machinery and parts, fell by 43.3% to $ 1.28 billion in 2010 from $2.25 billion in 2009.  During the year 2007, the US imports to India included exceptionally large imports of aircraft /parts, which resulted in a leap in the growth rate of US exports to 54.7%. With this component excluded, the growth rates of US exports in 2007 and 2008 are 37.5% and 39.9% respectively.

 International Pharmaceutical Supply Chains Include Indian Active Pharmaceutical Ingredient (API) Manufacturers, Indian Pharmaceutical Intermediate Manufacturers, and Indian Pharmaceutical Excipient Manufacturers All of Which Can Cause Adulterated and Dangerous Pharmaceuticals if Pharmaceutical Supply Chain Fraud Occurs

Included in the increased U.S.-India trade is the globalization of the pharmaceutical industry and other manufacturing industries.  This manufacturing globalization includes a shift in many international manufacturing supply chains where raw material supplies for pharmaceuticals, medical supplies, and medical equipment that were traditionally from the United States and Europe are now being produced in India as well as other emerging countries.  This manufacturing shift create has created an environment where adulterated ingredients to pharmaceuticals, medical supplies, and medical devices may be used in the manufacturing of these products and can create dangerous and defective drugs, medical supplies, and medical devices being purchased by governments and given to patients. 

In the fiercely competitive medical device, medical supply, and pharmaceutical markets, there are strong economic incentives to search for the cheapest ingredients and methods to produce products.  Often these cheaper ingredients and manufacturing locations are in countries where standards and regulations are less stringent and corruption is more common.  When large corporations set up subsidiaries and joint venture partners in these countries, good manufacturing practices can often suffer, fraudulent actors can cut corners to reduce costs, and cheaper sometimes toxic materials can be added to the products.

Further, supply chains that are bigger and more complex present more opportunities for fraud.  As such, when a large corporation has a supply chain with several international subsidiaries and joint venture partners throughout the world, there are numerous opportunities along the supply chain for fraud to occur including supplier fraud, purchase order fraud, good manufacturing practices fraud, inventory fraud, documentation fraud, export fraud, import fraud, and other pharmaceutical fraud.

Pharmaceutical suppliers of raw materials to the pharmaceutical industry include suppliers of active pharmaceutical ingredients (APIs), intermediates, and excipients.   It is the United States Food and Drug Administration's expectation that current good manufacturing practices (CGMP) be used for the manufacturing, processing, packing, or holding (i.e., storage) of active pharmaceutical ingredients (APIs), intermediates, and excipients.  Further, the FDA recommends that laboratory controls should include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures to ensure that raw materials, intermediates, APIs, and containers conform to established standards of quality and purity.

Typically, pharmaceutical manufacturing occurs in two general steps. First, firms convert raw materials into APIs. Then, firms create final formulations by mixing APIs and excipients (other non-active ingredients), pressing the mixture into tablets, or filling capsules or preparing solutions, and then packaging the product for the consumer market.

As such, raw material supplies for pharmaceuticals, medical supplies, and medical equipment that have traditionally come from the United States and Europe are now coming from China and India.  This manufacturing shift has created an environment where adulterated ingredients to pharmaceuticals, medical supplies, and medical devices may be used in the manufacturing of these important products and can create dangerous and defective drugs, medical supplies, and medical devices.  International Whistleblowers along the pharmaceutical supply chain are needed to blow the whistle on adulterated pharmaceutical ingredients that are being put into medicine, drugs, medical supplies, and medical devices.  For information on how to report adulterated pharmaceutical ingredients or illegal bribes along the pharmaceutical supply chain, please feel free to send an e-mail message to International Pharmaceutical Supply Chain Fraud Whistleblower Reward Lawyer, International Adulterated Drug Whistleblower Lawyer, and International Pharmaceutical Executive Whistleblower Reward Lawyer Jason Coomer or go to the following web page for more information on this topic: International Pharmaceutical Supply Chain Fraud Whistleblower Lawsuits

India Government Procurement Bribe Whistleblower Rewards, India Procurement Bribe Whistleblower Lawsuits, India Procurement Illegal Kickback Bounty Actions, and India Government Procurement Foreign Corrupt Practices Act Lawsuit Information

India government procurement whistleblowers can recover large amounts of money for exposing international government procurement kickback schemes, international government bribery schemes, and other violations of the Foreign Corrupt Practices Act.  Some types of these international government procurement illegal bribery schemes, international illegal kickback schemes, and other international illicit payment schemes are discussed in more detail on the following webpage: International Procurement Bribe Whistleblower Reward Lawsuit Information.

International executives, government officials, employees of international corrupt corporations, competitors of corrupt international corporations, and other persons, who are the original source of specialized knowledge of India government procurement bribes, India international public works illegal kickback schemes, India public health system procurement bribery schemes, and other India illicit payments by foreign and multinational corporations are encouraged to blow the whistle on international government procurement schemes and may be able to collect large financial rewards for exposing the corruption. 

For more information on a potential Foreign Corrupt Practices Act Whistleblower Reward Lawsuit, please feel free to send an e-mail message to International Government Procurement Bribe Whistleblower Attorney, Public Procurement Illegal Bribe Whistleblower Lawyer, and Government Purchasing Bribe Whistleblower Reward Attorney Jason Coomer or use our submission form to discuss a potential International Public Procurement Whistleblower Reward Lawsuit, International Government Procurement Whistleblower Reward Lawsuit, International Government Purchase Contract Bribe Whistleblower Lawsuit, Government Procurement Illegal Kickback Lawsuit, or other Government Official Procurement Bribe Foreign Corrupt Practices Act Whistleblower Lawsuit. 

India Supply Chain Fraud Whistleblower Reward Lawyers, India Government Official Bribe Whistleblower Lawyers, India Construction Contract Bribe Whistleblower Lawyers, India Drug Contract Bribe Whistleblower Lawyers, India Medicine Contract Illegal Kickback Lawyers, and India Chain Foreign Corrupt Practices Act Lawyers

As an International India Bribe and Corrupt Practices Whistleblower Reward Lawyer, Jason Coomer works with other powerful international whistleblower lawyers that handle large international whistleblower reward cases.  He works with Los Angeles International Whistleblower Reward Lawyers, San Antonio Health Care Procurement Fraud Lawyers, New York International Whistleblower Reward Lawyers, Dallas Health Care Fraud Whistleblower Lawyers, San Francisco International Import Export Fraud Lawyers, Houston International Medicine Supply Chain Fraud Whistleblower Lawyers, and other International Public Health Procurement Fraud Whistleblowers  throughout the United States and the world to blow the whistle on corruption and fraud. 

India Supply Chain Fraud Whistleblower Reward Lawyer, India Government Official Bribe Whistleblower Lawyer, India Construction Contract Bribe Whistleblower Lawyer, India Drug Contract Bribe Whistleblower Lawyer, India Medicine Contract Illegal Kickback Lawyer, and India Chain Foreign Corrupt Practices Act Lawyer

If you are an international executive, government official, international pharmaceutical company professional, international pharmaceutical company executive, international medical device professional, international medical device executive, public health administrator, medical doctor, or other professional with original source knowledge of a potential India Pharmaceutical Supply Chain Whistleblower Reward Lawsuit, India Adulterated Drug Whistleblower Reward Lawsuit, India Counterfeit Drug Ingredient Whistleblower Lawsuit, India Toxic Medication Illegal Kickback Lawsuit, India Government Procurement Bribe Whistleblower Reward Lawsuit, India Foreign Corrupt Practices Act Violation Lawsuit, or other fraudulent and corrupt act that could lead to an International Whistleblower Reward Lawsuit, please contact an international foreign corrupt practice act whistleblower reward lawyer to help expose the wrongdoing and protect yourself.

International whistleblowers including India whistleblowers and professionals along supply chains are needed to blow the whistle on corrupt practices and adulterated pharmaceutical ingredients that are being put into medicine, drugs, medical supplies, and medical devices.  For information on reporting government corruption, adulterated pharmaceutical ingredients or illegal bribes along the pharmaceutical supply chain, please feel free to send an e-mail message to India Contract Bribe Whistleblower Reward Lawyer, India Adulterated Drug Whistleblower Lawyer, and India Foreign Corrupt Practices Act Lawyer Jason Coomer

Feel Free to Contact Us
with any Questions
* Name (Required):
* Email (Required):
Phone Number:
* Your Message (Required):
Anti-spam Question:
*Using only numbers,
what is 2 plus 2?

FedGovFraud.com

Illegal Kickback Lawsuits

FCPA Lawsuits

SEC Violation Lawsuits

Securities Fraud Litigation